| Document |
Document Title |
|
WO/2024/010219A1 |
The present invention relates to a growth promotion composition comprising a peptide consisting of Asp-Lys-Phe-Leu-Asp. If the peptide consisting of Asp-Lys-Phe-Leu-Asp, of the present invention, is used, growth is promoted and the quali...
|
|
WO/2024/004747A1 |
The present invention addresses the problem of providing a transplant material suitable for clinical application, without using an artificial material. The problem is solved by providing a method for producing a cellular structure, the m...
|
|
WO/2024/005178A1 |
The present invention provides a non-aqueous preparation that comprises 5-ALA, a derivative thereof, or a salt of these, and that has excellent stability of the 5-ALA, the derivative, or the salt of these. A non-aqueous preparation accor...
|
|
WO/2024/005526A1 |
The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhib...
|
|
WO/2024/005158A1 |
The problem addressed by the present invention is to identify a cis element that negatively regulates translation to protein present in DGCR8 mRNA or DGCR8 pre-mRNA, to provide an oligonucleotide capable of promoting expression of DGCR8 ...
|
|
WO/2024/002960A1 |
The present invention relates to a method for increasing the Ievels of oleacein in an olive tree leaves extract, wherein olive tree leaves are frozen and pre-treated by freeze drying and ground before being extracted to obtain an olive t...
|
|
WO/2024/005587A1 |
The present invention relates to a use of an isoxazole derivative or a pharmaceutically or sitologically acceptable salt thereof, which regulates the level of intestinal microorganisms in a subject suffering from liver disease, gastroint...
|
|
WO/2024/004869A1 |
The present invention provides a peptide that can be utilized in active targeting DDS. Provided according to an embodiment of the present invention are: a peptide that has a hydrophobic region and a hydrophilic region lower in hydrophobi...
|
|
WO/2024/006305A1 |
The present disclosure relates generally to compositions of nitroglycerin and related organic nitrates, and methods for treating conditions such as Raynaud's phenomenon in which peripheral blood flow in a subject is compromised.
|
|
WO/2024/005157A1 |
The purpose of the present invention is to provide: a novel adipocyte activator; and a use thereof. The present invention provides an adipocyte activator containing SerpinA1, a SerpinA1 expression promoter, or a SerpinA1 agonist, wherein...
|
|
WO/2024/004656A1 |
Provided is a pharmaceutical composition that is a composition for treating an immune-related adverse event (irAE) in a subject who has undergone a cancer immunotherapy, the pharmaceutical composition containing anthracycline.
|
|
WO/2024/004231A1 |
The present invention addresses the problem of providing a novel γ-secretase inhibitor that has as an active ingredient a substance for which a γ-secretase inhibitory activity is heretofore unknown. The present invention provides a γ-...
|
|
WO/2024/003371A1 |
The present invention relates to compositions comprising a methyl group donor compound and an acetyl-CoA donor compound for use in therapy and prevention of diseases associated with dysfunction of mitochondriae, wherein the diseases asso...
|
|
WO/2024/005124A1 |
The present invention relates to: a method for producing a non-human primate model of cerebral infarction, said method including administering an endothelin to the cerebral basal ganglia and thalamic area of a non-human primate and thus ...
|
|
WO/2024/000401A1 |
The present invention relates to compounds of formula (I) preferred compounds are e.g. 2-((l-(4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives of formula (ll-A) an exemplary compound is e.g. 2-((l-(2-(isoindolin-2-yl...
|
|
WO/2024/005586A1 |
The present invention relates to a novel crystalline form of 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazo
l-4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-
7-carboxylic acid or a salt thereof.
|
|
WO/2023/249046A1 |
[Problem] To provide a composition (a cosmetic, etc.) for maintaining the structure of hyaluronic acid in human skin and the like, and/or a material (an agent) to be used therein, etc. [Solution] An agent for maintaining the structure of...
|
|
WO/2023/248845A1 |
The present invention provides: a novel PTX3 expression control agent that uses miRNA from fine particles to control PTX3 expression, the PTX3 expression control agent including fine particles that include miRNA that targets a gene relat...
|
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
|
WO/2023/248844A1 |
Provided are: an HMGB1 expression suppressor comprising a microparticle, in which the microparticle contains miRNA of which the target gene is a gene associated with the expression of HMGB1, the HMGB1 expression suppressor being a novel ...
|
|
WO/2023/250063A1 |
A method of treating a patient with intestinal radiation injury is disclosed. The method includes administering an effective amount of a geranylgeranyl transferase inhibitor to a patient with intestinal radiation injury. In one aspect, t...
|
|
WO/2023/249049A1 |
Provided is a composition capable of inhibiting peritoneal deterioration. A peritoneal deterioration inhibiting composition according to the present invention comprises carbon monoxide.
|
|
WO/2023/248744A1 |
Provided is a treatment method that provides a better response rate and/or life-extending effectiveness in nonhuman mammals with cancer. Provided are: a method for treating cancer in non-human mammals, the method comprising starting tr...
|
|
WO/2023/249078A1 |
The purpose of the present invention is to provide a senescence inhibitor that utilizes a material of biological origin. The present invention is directed to a senescence inhibitor containing a vitamin D binding protein.
|
|
WO/2023/249651A1 |
The disclosed invention relates to a composition for effective management of peritonitis in a subject. The invention also discloses a composition for preventing peritonitis mediated multi organ dysfunction in a subject. It also covers co...
|
|
WO/2023/249087A1 |
Provided is a pharmaceutical composition or the like having a new form that can be orally administered even when the contained medicinal effect component is a medicinal effect component such as a high molecular weight component. This p...
|
|
WO/2023/247592A1 |
The present invention relates to 5-(4-fluorophenyl)-2,3-dihydro-1H- imidazo[1,2-a]imidazole derivatives of formula (I) as ALK5 inhibitors (transforming growth factor 3 (TGF3) type 1 receptor) for the treatment of fibrosis, such as e.g. p...
|
|
WO/2023/250031A1 |
The present invention relates to pharmaceutical compositions of docosahexaenoic acid (DHA) analogs for treating hearing and ocular disorders.
|
|
WO/2023/249017A1 |
The present invention uses a lactic acid bacteria fermentation product of sap of a plant of the genus Betula as an active ingredient of an anti-aging agent, hair growth agent, and anti-androgen agent. An anti-aging agent, hair growth age...
|
|
WO/2023/249075A1 |
The purpose of the present invention is to provide a prophylactic, therapeutic or ameliorating drug or food for non-alcoholic steatohepatitis-derived hepatocarcinoma. The present invention pertains to a CD36 inhibitor comprising taxifoli...
|
|
WO/2023/249105A1 |
The purpose of the present invention is to provide a therapeutic agent or a preventive agent for drug-induced myocardial disorders and having ferroptosis inhibitory action. The present invention provides a therapeutic agent or a preven...
|
|
WO/2023/249423A1 |
The present invention relates to a composition comprising Lactobacillus gasseri for preventing and treating sarcopenia and, particularly, to: a composition comprising Lactobacillus gasseri BNR17 for preventing, treating or alleviating sa...
|
|
WO/2023/243686A1 |
The present invention provides a compound that exhibits a PLD-inhibitory activity. The present invention provides a compound having the following structural formula or the like, or a pharmaceutically acceptable salt thereof. (Each symb...
|
|
WO/2023/240379A1 |
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, ste...
|
|
WO/2023/243616A1 |
Provided is a crystal of a dihydropyridinone derivative or a solvate thereof. The present invention relates to: a crystal of a compound represented by the formula, or a solvate thereof; and a pharmaceutical composition containing the s...
|
|
WO/2023/242605A1 |
The invention relates to algal extracellular vesicles (EVs) for use in therapy and in restoring or maintaining health of a subject. In particular the invention relates to uses of algal EVs in therapy, wherein the EVs themselves have favo...
|
|
WO/2023/243689A1 |
The present invention provides: a sepsis and/or septic shock therapeutic agent containing, as an active ingredient, a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidat...
|
|
WO/2023/243210A1 |
Provided are a myoblast proliferation promoting agent and a muscular atrophy inhibiting agent that contain a compound represented by structural formula (1).
|
|
WO/2023/243659A1 |
Provided is a pharmaceutical composition for treating obsessive-compulsive disorder. The present invention pertains to: (1) a pharmaceutical composition containing a dopamine D1 receptor stimulant as an active ingredient for treating o...
|
|
WO/2023/245055A1 |
The present disclosure relates to dosing regimens and methods for treatment of X-linked adrenoleukodystrophy (X-ALD) using thyroid receptor beta agonists.
|
|
WO/2023/242599A1 |
The present inventions concerns the use of compositions comprising a benzimidazole compound with antihelminthic activity for use in reversing, arresting or slowing down cellular ageing in a vertebrate subject. In preferred embodiments th...
|
|
WO/2023/240326A1 |
The present invention relates to the industrial process and use of a liquid probiotic composition administered to poultry for greater tolerance to heat stress, i.e., high temperatures. The technical solution achieved by the present inven...
|
|
WO/2023/241119A1 |
Disclosed is use of chaetocin in anti-aging. The present invention adopts an aging cell model and an aging mouse model to screen and obtain a drug, chaetocin, which has the effect of anti-aging. By means of cell and mouse experiment veri...
|
|
WO/2023/242810A1 |
The present invention relates to uses of a melanin-concentrating hormone receptor 1 (MCHR1) antagonist, e.g., a compound of formula (I), or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions thereof for the treatm...
|
|
WO/2023/243447A1 |
The purpose is to clarify the internal structures of the skin related to sagging and to provide a novel cosmetic method for preventing and improving sagging. Firmness of the skin was discovered to be due to circular collagen in the dermi...
|
|
WO/2023/241496A1 |
Provided in the present invention are a composition for promoting the migration, homing and implantation of hematopoietic stem progenitor cells and the use thereof. The composition contains a corticotropin-releasing hormone. The composit...
|
|
WO/2023/242070A1 |
The invention relates to phenylene diamine derivatives with certain pharmacological properties resulting from enhancement of epithelial barrier function and/or blocking bacterial translocation through the epithelial barrier. The compound...
|
|
WO/2023/241669A1 |
Provided are a CRISPR-Cas effector protein, a gene editing system therefor, and an application. The CRISPR-Cas effector protein comprises a protein which is at least 70% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to...
|
|
WO/2023/239227A1 |
The present invention relates to a novel compound that regulates the function and differentiation of the cytoskeleton, which is involved in pulmonary fibrosis, and thus is useful in the preparation of drugs that can treat associated dise...
|
|
WO/2023/239892A1 |
Provided herein are methods of modulating CD68, or treating CD68-associated disorders, by using a compound as disclosed herein.
|
